Literature DB >> 11208693

Oral matrix metalloproteinase inhibition and arterial remodeling after balloon dilation: an intravascular ultrasound study in the pig.

M J Sierevogel1, G Pasterkamp, E Velema, P P de Jaegere, B J de Smet, J H Verheijen, D P de Kleijn, C Borst.   

Abstract

BACKGROUND: Inhibition of matrix metalloproteinase (MMP) activity after balloon angioplasty by intraperitoneal injection of batimastat reduces late lumen loss by inhibition of constrictive remodeling. In the present study, we investigated whether the oral MMP inhibitor marimastat inhibits constrictive remodeling in favor of neutral or expansive remodeling. METHODS AND
RESULTS: In 26 pigs, balloon dilation was performed in 101 peripheral arteries. Pigs were treated with marimastat or served as controls and were euthanized 42 days after intervention. Intravascular ultrasound was performed at all time points. Vessel area (VA) loss was assessed by calculating the change in VA at termination relative to after intervention. Arteries were divided in 3 categories: expansive remodeling (VA loss < -5%), neutral (-5% <or= VA loss <or= +5%), and constrictive remodeling (VA loss > +5%). In the marimastat group, a significant reduction (53%) of late lumen loss was observed that was fully explained by impaired constrictive remodeling. In the marimastat group, the prevalence of constrictive remodeling was reduced (38% versus 75% in the control group) in favor of not only neutral but also expansive remodeling (21% and 42% versus 4% and 21% in the control group, respectively, P:<0.01). In contrast to the control group, acute luminal gain in the marimastat group did not correlate with late VA loss.
CONCLUSIONS: Irrespective of the acute luminal gain by balloon dilation, the oral MMP inhibitor marimastat inhibited constrictive arterial remodeling in favor of both neutral and expansive remodeling.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11208693     DOI: 10.1161/01.cir.103.2.302

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

1.  Matrix metalloproteinases and small artery remodeling.

Authors:  Luis A Martinez-Lemus; Edgar Luis Galiñanes
Journal:  Drug Discov Today Dis Models       Date:  2011

2.  MMP-9 regulates both positively and negatively collagen gel contraction: a nonproteolytic function of MMP-9.

Authors:  Olivier D Defawe; Richard D Kenagy; Chun Choi; Samuel Y C Wan; Christophe Deroanne; Betty Nusgens; Natzi Sakalihasan; Alain Colige; Alexander W Clowes
Journal:  Cardiovasc Res       Date:  2004-12-15       Impact factor: 10.787

Review 3.  Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.

Authors:  Y Y Li; A M Feldman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Doxycycline alters vascular smooth muscle cell adhesion, migration, and reorganization of fibrillar collagen matrices.

Authors:  Christopher Franco; Bernard Ho; Diane Mulholland; Guangpei Hou; Muzharul Islam; Katey Donaldson; Michelle Patricia Bendeck
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

5.  A nonantibiotic chemically modified tetracycline (CMT-3) inhibits intimal thickening.

Authors:  Muzharul M Islam; Christopher D Franco; David W Courtman; Michelle P Bendeck
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

6.  Systemic Delivery of Nanoparticles Loaded with Pentagalloyl Glucose Protects Elastic Lamina and Prevents Abdominal Aortic Aneurysm in Rats.

Authors:  Nasim Nosoudi; Aniqa Chowdhury; Steven Siclari; Vaideesh Parasaram; Saketh Karamched; Naren Vyavahare
Journal:  J Cardiovasc Transl Res       Date:  2016-08-19       Impact factor: 4.132

7.  Liposomal prednisolone inhibits vascular inflammation and enhances venous outward remodeling in a murine arteriovenous fistula model.

Authors:  ChunYu Wong; Taisiya Bezhaeva; Tonia C Rothuizen; Josbert M Metselaar; Margreet R de Vries; Floris P R Verbeek; Alexander L Vahrmeijer; Anouk Wezel; Anton-Jan van Zonneveld; Ton J Rabelink; Paul H A Quax; Joris I Rotmans
Journal:  Sci Rep       Date:  2016-07-27       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.